Results 11 to 20 of about 155,806 (387)
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade [PDF]
Nature Communications, 2019 Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade ...
Seungwon Yang +10 more
semanticscholar +3 more sources
YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma
Frontiers in Oncology, 2019 YTH N6-methyladenosine (m6A) RNA binding protein 1 (YTHDF1) is a core factor in RNA methylation modification. Recent studies have shown that m6A is closely related to multiple tumors, thus YTHDF1 may also play a role in tumorigenesis.
Yang Bai +9 more
doaj +2 more sources
Stable suppression of tumorigenicity by virus-mediated RNA interference [PDF]
Cancer Cell, 2002 Thijn R. Brummelkamp +2 more
openalex +2 more sources
Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider [PDF]
Cytotherapy, 2019 Yoji Sato +15 more
openalex +2 more sources
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity
Nature Cancer, 2023 The transfer of intact mitochondria between heterogeneous cell types has been confirmed in various settings, including cancer. However, the functional implications of mitochondria transfer on tumor biology are poorly understood.
Dionysios C. Watson +41 more
semanticscholar +1 more source
Bioengineering, 2023 Stem cells hold promise in regenerative medicine due to their ability to proliferate and differentiate into various cell types. However, their self-renewal and multipotency also raise concerns about their tumorigenicity during and post-therapy.
Zongjie Wang
semanticscholar +1 more source
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Cancers, 2022 Simple Summary Cancer-associated fibroblasts (CAFs) are found in the tumor microenvironment and exhibit several protumorigenic functions. Preclinical studies suggest that CAFs can be reduced, eliminated, or reprogrammed; however, clinical translation has
Raisa A. Glabman, P. Choyke, Noriko Sato
semanticscholar +1 more source
Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity. [PDF]
, 2012 Although chemotherapy is used to treat most advanced solid tumors, recurrent disease is still the major cause of cancer-related mortality. Cancer stem cells (CSCs) have been the focus of intense research in recent years because they provide a possible ...
de la Cruz, Cecile +5 more
core +11 more sources
Nature Communications, 2021 Hypercholesterolemia and dyslipidemia are associated with an increased risk for many cancer types and with poor outcomes in patients with established disease.
Wen Liu +5 more
semanticscholar +1 more source
Tumorigenicity risk of iPSCs in vivo: nip it in the bud
Precision Clinical Medicine, 2022 In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of
Chaoliang Zhong +3 more
semanticscholar +1 more source